Related Experiment Video
Updated: Nov 27, 2025
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention
Rachel Hellemans1,2, Daniel Abramowicz1,2
1Department of Nephrology, Antwerp University Hospital, Antwerp, Belgium.
Abstract:
Cytomegalovirus (CMV)-related complications after kidney transplantation remain a substantial challenge. Rather than applying one preventive strategy to all at-risk patients, we can now adapt our strategy at the individual patient level. Antiviral prophylaxis or a strict pre-emptive strategy may be optimal for patients at the highest risk for CMV, while patients at lower risk may benefit particularly from pre-emptive monitoring and the administration of therapy only if needed. CMV-specific T-cell assays may be useful for further refining the pre-transplant determination of CMV risk, and for guiding decisions about antiviral therapy need or duration. An immunosuppressive regimen including a mammalian target of rapamycin inhibitor reduces CMV risk and may thus be an attractive option in some patients. New antiviral agents may further expand our therapeutic arsenal in the near future, and the prospects of CMV vaccination and adoptive T-cell therapy appear to be on the horizon.
Insights
Personalized strategies for cytomegalovirus (CMV) in kidney transplant recipients are key. Tailoring antiviral prophylaxis or pre-emptive monitoring based on individual risk optimizes outcomes and reduces CMV complications.
Area of Science:
- Nephrology
- Transplantation Immunology
- Infectious Diseases
Background:
- Cytomegalovirus (CMV) complications pose a significant challenge post-kidney transplantation.
- Current management often involves a one-size-fits-all approach to prevention.
Purpose of the Study:
- To explore individualized strategies for CMV prevention and management in kidney transplant recipients.
- To highlight the role of risk stratification and novel diagnostic tools.
Main Methods:
- Review of current and emerging approaches to CMV management.
- Discussion of risk stratification using CMV-specific T-cell assays.
- Evaluation of immunosuppressive regimens and novel therapeutic agents.
Main Results:
- Individualized strategies, including tailored prophylaxis or pre-emptive monitoring, are superior to uniform approaches.
- CMV-specific T-cell assays aid in refining risk assessment and guiding therapy.
- Mammalian target of rapamycin inhibitors may reduce CMV risk.
Conclusions:
- Personalized CMV management in kidney transplant patients improves outcomes.
- Future directions include new antiviral drugs, vaccination, and adoptive T-cell therapy.
More Related Videos
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:16Kidney Transplant III: Nursing Management
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:26Kidney Transplant II: Surgical Procedure
01:25Chronic Kidney Disease I: Introduction
01:22Acute Kidney Injury I: Introduction